medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Psilocybin produced a rapid and sustained reduction in depressive and anxiety symptoms in patients with major depressive disorder and in those with life-threatening cancer. MDMA reduced depressive symptoms in patients with life-threatening cancer, autism spectrum disorder, and post-traumatic stress disorder, and reduced social anxiety, but its effect on anxiety symptoms overall was negligible or negative. Ayahuasca reduced depressive symptoms in individuals with treatment-resistant major depressive and personality disorders. LSD reduced anxiety symptoms in individuals with life-threatening cancer. Adverse effects included elevated blood pressure, headaches, and panic attacks for psilocybin and MDMA, plus feeling cold for MDMA.
medRxiv
May 10, 2023
Victoria di Virgilio, Amir Minerbi, Jagpaul Kaur Deol et al.
preprint
Veterans and civilians who used psychedelic medicines for non-recreational purposes in the previous three years reported improvements across pain, mental health, function, and overall quality of life, with the largest perceived gains in mental health and quality of life and the smallest in pain. Correlations among these domains were highly significant, particularly between function, quality of life, and mental health. No significant differences emerged between specific psychedelic drugs, suggesting the benefits may be class-wide. The study was retrospective, anonymous, and relatively small (65 participants), and lacked a baseline comparison.
medRxiv
December 26, 2022
Jeremy Weleff, Akhil Anand, Elizabeth N. Dewey et al.
preprint
Lysergic acid (LSD) use in the United States rose by 47% from 2015 to 2019, from 0.59% to 0.87% of the population. However, among people reporting past-year hallucinogen use disorder, there was no significant proportional increase in LSD users. Correlates of LSD use included increased access, lower perceived risk, Asian race, low income, fewer children at home, history of selling drugs, recent drug solicitations, lack of religious influence on decisions, and past-year suicide attempt among adults. No associations were found with unemployment, arrest history, psychological distress, or sexually transmitted infections. The proportion of pregnant, married, and 26–34-year-old LSD users increased, as did LSD use among lifetime methamphetamine users.
medRxiv
June 16, 2022
Caroline L. Alves, Thaise G. L. de O. Toutain, Joel Augusto Moura Porto et al.
preprint
A machine-learning method using support vector machines classified EEG data from volunteers before and after inhaling the psychedelic DMT. Complex network measures derived from brain connectivity achieved 89% AUC, outperforming raw connectivity matrices. Key distinguishing features included connections between temporal and central cortex regions (TP8-C3) linked to finger movements, and between precentral gyrus and lateral occipital cortex (FC5-P8) potentially related to emotional and mystical experiences. Closeness centrality was the most important network measure. DMT increased community size and average path length, disrupting the balance between functional segregation and integration, supporting the idea that cortical activity becomes more entropic under psychedelics.
medRxiv
April 16, 2022
Yann Barguil, Laura Chiaradia, Guy Southwell et al.
preprint
Among young cannabis consumers, a brief psychotic disorder may signal either acute cannabis psychosis or the onset of schizophrenia, yet no clinical or paraclinical criteria reliably differentiate them. In a study of 256 New Caledonian cannabis users, delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in head hair were measured at initial psychiatric consultation and after a 6-month follow-up. A high hair THC level (>0.7 ng/mg) combined with a low CBD/THC ratio (<0.26) emerged as a potential marker for chronic psychosis. For acute cannabis psychosis, the CBD/THC ratio was higher (>0.43) than for other personality disorders (<0.32). The findings suggest CBD may protect against THC's harmful effects, and hair cannabinoid analysis could aid psychiatric diagnosis and early management.
medRxiv
March 2, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
preprint
In a group of 52 healthy volunteers attending psilocybin ceremonies, consuming an average of 27.1 mg of psilocin led to medium to large reductions in both state and trait anxiety that persisted for at least one week. One week after the ceremony, participants showed increased non-judging mindfulness and decreased neuroticism. The strongest predictors of reduced trait anxiety were lower neuroticism, and for state anxiety, higher ego dissolution during the experience. The findings suggest rapid and lasting anxiolytic effects of psilocybin in a supportive setting, but further research is needed to confirm these effects in clinical populations.
medRxiv
January 31, 2022
Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al.
preprint
Male patients with new-onset Cannabis Induced Psychotic Disorder (CIPD) present with less severe psychotic symptoms and show greater improvement in both psychosis and cognitive deficits over four weeks of hospitalization compared to patients with psychosis unrelated to cannabis. Among 16 CIPD patients followed after discharge, 10 relapsed into psychosis within six months after resuming cannabis use. The findings suggest CIPD has a distinct short-term course with better acute resolution, but relapse of cannabis use may lead to poorer long-term outcomes. The study did not include female patients.
medRxiv
Klemens Egger, Daniel Meling, Firuze Polat et al.
preprint
In a double-blind, placebo-controlled pharmaco-fMRI study, 40 meditation practitioners on a three-day retreat received either placebo or buccal DMT-harmine (120 mg each). Meditation alone increased network segregation across several resting-state networks, while DMT-harmine increased functional connectivity within the visual network and between visual and attention networks. Between-group differences showed increased connectivity between visual and salience networks in the DMT-harmine group. No prolonged cortical gradient disruption was observed, indicating a return to typical brain organization shortly after the experience. Meditation reduced connectivity between networks, whereas DMT-harmine increased within- and between-network connectivity, revealing distinct neural mechanisms.
medRxiv
November 20, 2025
Qing Wang, Lizhao Du, Jialing Sheng et al.
preprint
An eight-month randomized clinical trial of male inpatients with schizophrenia found that daily clinician-guided meditation plus rehabilitation improved symptoms by 11.8% at 3 months and 20.8% at 8 months, and improved cognition by 7.6% at 3 months, which then plateaued. Early cognition improvement predicted but did not mediate later symptom relief. Brain imaging revealed a biphasic pattern: baseline default-mode-cerebellar complexity predicted 3-month benefit, while 3-month action-mode/sensorimotor-executive complexity predicted 8-month gains. These findings support a biphasic network reconfiguration model for meditation in schizophrenia and suggest phase-specific markers for personalized treatment.
medRxiv
June 9, 2025
preprint
This protocol describes a planned systematic review and individual patient data meta-analysis of randomised controlled trials to assess the efficacy and moderators of Mindfulness-Based Cognitive Therapy (MBCT) for people with 'difficult to treat' depression. The review will synthesize existing trial data to determine how well MBCT works and for whom it is most effective.
medRxiv
January 6, 2023
preprint
A brief mindfulness-based intervention reduced the automatic influence of alcohol-related cues on instrumental behavior in people with alcohol use disorder. Participants who received the mindfulness training showed weaker Pavlovian-to-instrumental transfer effects compared to a control group, suggesting that mindfulness may help disrupt cue-triggered drinking habits. The findings indicate that even a short mindfulness intervention can alter implicit motivational processes underlying addiction.
medRxiv
November 24, 2021
preprint
Mindfulness, both as a stable personality trait and as a temporary state induced by meditation, alters the brain's electrical activity patterns measured by EEG microstates. The findings suggest that individuals with higher trait mindfulness show different microstate dynamics at rest, and a brief mindfulness induction shifts these patterns in a similar direction. These results indicate that mindfulness is associated with changes in the brain's large-scale network configurations, potentially reflecting improved attentional regulation and self-awareness.